71 results about "Lipid lowering" patented technology

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

This invention discloses the application of α-hydroxyisocaproic acid in weight loss and lipid reduction, belonging to the fields of biopharmaceutical manufacturing, biomedical applications, and functional food development. This invention confirms the application of α-hydroxyisocaproic acid in weight loss; this compound can inhibit weight gain in high-fat diet-induced obese mouse models, reduce body fat, and decrease the area of ​​adipocytes in high-fat diet-induced obese mouse models. Compared to GLP-1 receptor weight-loss drugs that reduce weight by suppressing appetite, the compound α-hydroxyisocaproic acid intervenes in and prevents obesity by accelerating fat metabolism, thereby achieving weight reduction. This invention provides a safe and effective new strategy for weight loss and lipid reduction.

The application discloses Ixeris sonchifolia Hance polysaccharides, a preparation method and application thereof, belongs to the technical field of plant polysaccharides, and provides polysaccharides ISP-1a and ISP-2a, wherein the ISP-1a has a molecular weight of 2086 Da and is composed of seven monosaccharides of mannose, rhamnose, glucuronic acid, glucose, galactose, xylose and arabinose; the ISP-2a has a molecular weight of 1781 Da and is composed of five monosaccharides of mannose, rhamnose, galacturonic acid, xylose and arabinose. The whole grass of Ixeris sonchifolia Hance is subjected to hot water extraction after ethanol degreasing, neutral enzyme + Sevage method is used to remove protein, macroporous resin is used for decolorization, column chromatography elution is carried out, purification is carried out, and two kinds of uniform polysaccharides are obtained after freeze-drying. The polysaccharides ISP-1a and ISP-2a have good antioxidant and lipid-lowering effects, and can be applied to the preparation of food, health products or medicines with antioxidant and lipid-lowering functions.

This invention relates to the field of functional food technology, and discloses a muscle-building, lipid-lowering, and weight-loss composition, its preparation method, and its application. The composition, by weight, comprises: 25-45 parts of complex protein peptides; 5-20 parts of fruit and vegetable powder; 2-8 parts of medicinal and edible extracts; 3-12 parts of complex prebiotics; 1-6 parts of complex vitamins and minerals; 0.5-3 parts of probiotics; 0.5-5 parts of calcium β-hydroxy-β-methylbutyrate; and the remainder being food-acceptable excipients. This invention achieves significant lipid-lowering and weight-loss while effectively increasing lean body mass and muscle mass, and the active ingredients exhibit good stability.

The application relates to the field of biological medicine, in particular to application of TDF in serum cholesterol regulation and a verification method. The application discloses that tenofovir disoproxil fumarate (TDF) can inhibit intestinal cholesterol absorption by specifically down-regulating the expression level of NPC1L1 protein in the intestinal tract, so as to reduce serum cholesterol. The regulation has tissue specificity, and TDF has no significant influence on the expression of key genes of liver cholesterol metabolism. The application also provides a method for verifying the regulation of TDF on serum cholesterol, which is evaluated by detecting blood lipid indexes and the gene and / or protein expression level of NPC1L1 in duodenal tissue. The application provides a treatment scheme with antiviral and cholesterol-lowering effects for patients with chronic hepatitis B combined with hypercholesterolemia, and provides a new idea for developing a lipid-lowering strategy targeting intestinal cholesterol absorption.

This invention relates to the field of health products or food technology, and more specifically to a composition and its application in removing dampness and controlling blood sugar, balancing blood pressure, and regulating blood lipids. The invention provides a composition for removing dampness and controlling blood sugar, balancing blood pressure, and regulating blood lipids, comprising Poria cocos extract, Astragalus membranaceus extract, hirudin, and at least one or more of Eucommia ulmoides extract, Gynostemma pentaphyllum extract, and Morus alba twig extract. The composition provided by this invention utilizes extracts from at least four precious Chinese medicinal herbs to exert a synergistic effect, jointly achieving the effects of lowering blood pressure, removing dampness and lowering blood sugar, and lowering blood lipids.

Provided are a traditional Chinese medicine composition for lipid reduction, a preparation method therefor, and use thereof. The traditional Chinese medicine composition comprises a lipid-reducing core component and auxiliary components. The lipid-reducing core component is composed of Mallotus oblongifolius and Dalbergiae Odoriferae Lignum, and the auxiliary components comprise Crataegi fructus and Salviae miltiorrhizae. The traditional Chinese medicine composition can ameliorate the hyperlipidemia condition and reduce the body weight of model animals, and can also reduce the expression of various inflammatory factors.

This invention belongs to the field of biomedicine, specifically relating to siRNA targeting the angiopoietin-like protein 3 gene and its applications. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-ended complementary nucleotide sequence; or a sense strand of 19 nucleotides and an antisense strand of 21 nucleotides with overhanging ends. The siRNA of this invention can comprehensively lower blood lipids, and has good lipid-lowering effects on triglycerides and LDL-C, helping to significantly reduce the risk of atherosclerosis and cardiovascular disease.

The present application provides a kind of whole fruit fruit wine, it is by fruit, 50 degrees of liquor base liquor, yellow sugar, honey proportion mixed soak and is made into.The fruit is unique plant in Wudang Mountain of Hubei, has the effect of generating fluid to quench thirst, clearing spirit and reducing qi, is respected as holy fruit in ancient times, Ming Dynasty emperor Zhu Di also lists fruit as tribute to the court.Fresh fruit contains rich phosphorus, iron, calcium, vitamin C, carotene and other nutrients and seventeen kinds of amino acids necessary for human body, has the effect of helping digestion, resolving phlegm, tonifying kidney, refreshing brain, invigorating blood, strengthening body, tranquilizing pain, reducing pressure and reducing lipid, also has the health care effect of anti-inflammatory analgesic, eliminating fatigue, detoxification, enhancing immunity, etc.The present application not only improves the utilization value of fruit, but also greatly improves the nutritional and health care function of fruit wine, with low cost, improves economic benefit, and creates good social benefit.

The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

An auxiliary lipid-lowering Camellia diacylglycerol edible oil and a preparation method thereof, involving grinding walnuts, peas, and sweet corn kernels, then thorough enzymatic hydrolysis; the obtained nutritious rapeseed oil is dispersed in the mixed edible oil, the prepared nutritious Camellia diacylglycerol oil mixture contains rich nutrients; the plant extract obtained by ultrasonic extraction is effectively adsorbed by the mixed colloid, the obtained nanoparticles that assist in lowering blood lipids and promoting metabolism cooperate with the nutritious Camellia diacylglycerol oil mixture to have an effective lipid-lowering effect; the antioxidant stabilizing composition and the nanoparticles that assist in lowering blood lipids and promoting metabolism are dispersed in the nutritious Camellia diacylglycerol oil mixture; the prepared auxiliary lipid-lowering Camellia diacylglycerol edible oil is rich in nutrition, does not increase blood lipids in the body after long-term consumption, doesn't cause damage to the liver and kidneys, and is not prone to deterioration.

The application belongs to the technical field of biological medicine, and discloses a novel polypeptide with lipid-lowering effect. In view of the problem that polypeptides are prone to be enzymolyzed in the gastrointestinal tract and difficult to play obvious effect in the body, a novel polypeptide is designed, and the amino acid sequence of the polypeptide is GQAIWMY. The polypeptide GQAIWMY has lipid-lowering capacity, is not prone to be degraded by gastrointestinal enzymes and is more stable, and can be used for preparing drugs for preventing or treating cardiovascular diseases (such as hyperlipidemia, atherosclerosis, coronary heart disease) and fatty liver diseases.

This invention belongs to the field of traditional Chinese medicine technology. More specifically, it relates to the application of a processed product of Citrus reticulata peel or Citrus reticulata peel embryo (with bitterness removed) in the preparation of products for lowering lipids and preventing and treating hyperlipidemia. Compared with the original product, the processed product of Citrus reticulata peel or Citrus reticulata peel embryo provided by this invention significantly reduces bitterness while significantly enhancing its effects in lowering cholesterol and triglycerides and regulating blood lipids. This processed product helps maintain normal levels of serum cholesterol, triglycerides, and low-density lipoprotein, and can significantly improve liver damage caused by hyperlipidemia, thus having important application value in lowering lipids and protecting the liver.

The present application relates to the application of pomelo powder or pomelo juice targeting GLP-1 receptor in the preparation of weight loss and blood glucose and blood lipid disorder improvement products, wherein the pomelo powder or pomelo juice is obtained by a preparation method comprising the following steps: reflux extraction after ultrasonic-assisted enzymatic hydrolysis of pomelo raw materials, and concentration of the filtrate after extraction, separation and purification to obtain pomelo powder or pomelo juice. The present application creatively uses pomelo peel and other tissues as raw materials, converts agricultural waste that is discarded or used at low value into high-value medical and functional food raw materials, and for the first time verifies that pomelo powder or pomelo juice can be used as a natural GLP-1R receptor agonist and can play an excellent role in reducing blood sugar and blood lipid and protecting the cardiovascular system. The present application creatively designs a specific extraction method for pomelo powder or pomelo juice, which can achieve excellent extraction effect and has strong practicability and adaptability.

A blood-clearing and lipid-lowering pill is composed of the following ingredients in the indicated weight ratios: Astragalus membranaceus 54-74, Salvia miltiorrhiza 54-74, Paeonia lactiflora 54-74, Carthamus tinctorius 33-53, Pheretima aspergillum 54-74, Hirudo medicinalis 33-53, Crataegus pinnatifida 54-74, Polygonum multiflorum 54-74, Cassia tora 54-74, Gastrodia elata 33-53, Uncaria rhynchophylla 54-74, Eucommia ulmoides 33-53, Achyranthes bidentata 54-74, Os draconis 54-74, Ostrea gigas 54-74, Prunella vulgaris 54-74, and Alisma plantago-aquatica 54-74. This invention can reduce blood viscosity to normal levels in a short period, allowing some patients with vascular stenosis exceeding 75% who require stents to avoid stent grafting, and enabling stroke patients to gradually recover their function.

This invention discloses a circular RNA agent targeting PCSK9 and its applications, relating to the field of biomedical technology. The circular RNA agent is a single-stranded closed-circular oligonucleotide containing an antisense sequence complementary to the transcription of the PCSK9 gene. It lacks free 5' and 3' ends, and does not contain overhangs, hairpin structures, or double-stranded regions. The molecules are linked by 3'-5' phosphodiester bonds. This circular RNA agent can be modified with GalNAc or prepared into pharmaceutical compositions for the treatment of diseases or conditions related to abnormal PCSK9 gene expression or activity. The circular RNA agent provided by this invention exhibits high stability, a long half-life, low immunogenicity, low modification toxicity, and high target gene inhibitory activity. It can significantly prolong the dosing interval, improve patient compliance, and provide a safer, longer-acting drug option for lipid-lowering therapy.

The present application provides a kind of pharmaceutical composition with lipid-lowering effect, including luteolin, isorhamnetin, 9-hydroxy-4,7-megastigme-3-ketone, lotus leaf base, 3-O-feruloyl quinic acid, kaempferol-3-O-acacia disaccharide-7-O-glucoside, kaempferol-3-O-beta-D-acacia glycoside and ginsenoside Rg1.The composition of example 1 has lipid-lowering efficacy verified by golden hamster hyperlipidemia model and AML12, HepG2 cell fatty degeneration model, the regulation effect of the composition of example 1 on the key target points of AMPK signal pathway and NF-κB signal pathway is verified by using molecular pharmacology experiment, and the mechanism of the composition of example 1 in treating hyperlipidemia by regulating energy metabolism and anti-inflammatory mechanism is described.

A lily and white kidney bean chewable tablet and its preparation method belong to the field of chewable tablet processing technology. The lily and white kidney bean chewable tablet comprises the following components in parts by weight: 20 parts dried lily powder, 25 parts white kidney bean powder, 10 parts maltodextrin, 5 parts sorbitol, 1 part magnesium stearate, 0.4 parts citric acid, and an appropriate amount of purified water. This invention disrupts part of the starch structure in lily, making its mucilage more easily absorbed by the human body. This component has an auxiliary effect on regulating blood lipids. The processing of white kidney beans avoids the phytohemagglutinin and trypsin inhibitors they contain, which hinder protein absorption and irritate the gastrointestinal tract. It also maximizes the retention of dietary fiber and B vitamins in white kidney beans, helping to control blood sugar and lower blood lipids.

This invention relates to a multi-effect synergistic lipid-lowering composition for food and its preparation method, belonging to the field of food technology. The composition includes the following raw materials: a compound fermentation broth, *Gynostemma pentaphyllum* extract, *Lycium chinense* root bark extract, and *Rosa rugosa* fruit extract. In the preparation of the compound fermentation broth, *Rosa laevigata*, mulberry twigs, and *Fritillaria cirrhosa* are co-fermented with a compound microbial culture consisting of *Pediococcus pentosaceus*, *Lactobacillus curvatureii*, and *Kluyveromyces lactis*. This fully utilizes the synergistic effects of the raw materials and the advantages of the fermentation process, further enhancing the antioxidant activity of the multi-effect synergistic lipid-lowering composition. Furthermore, this invention also uses *Gynostemma pentaphyllum*, *Lycium chinense* root bark, and *Rosa rugosa* fruit as raw materials to prepare extracts, which are then compounded as components of the multi-effect synergistic lipid-lowering composition. This effectively utilizes the lipid-lowering properties of different raw materials, synergistically enhancing their effects to achieve lipid-lowering and weight-loss effects.

The present invention relates to the technical field of lipid-lowering beverages, and particularly to a preparation method of a compound lipid-lowering mulberry leaf tea beverage and the compound lipid-lowering mulberry leaf tea beverage. The preparation method includes raw material pretreatment, primary fermentation conversion, co-inoculation of strains, compound fermentation culture, drying and aging, and preparation of the compound lipid-lowering mulberry leaf tea beverage. This process takes "the preparation of plant-derived functional beverages" as the core goal. By optimizing the pretreatment of the composite raw materials of mulberry leaves and dark tea, multi-strain co-fermentation conversion, directional blending and stability treatment of the beverage, the lipid-lowering effect is significantly verified by mouse experiments; at the same time, key problems such as the astringent taste, precipitation, and microbial safety of the beverage are solved, and a compound lipid-lowering mulberry leaf tea beverage with excellent sensory quality, convenient drinking, and safety and controllability is prepared.

The application provides a lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects and an application thereof, and belongs to the technical field of microorganisms. The lactobacillus sakei LN-Ls1 has a preservation number of CGMCC 30611. The LN-Ls1 strain is preserved in the China General Microbiological Culture Collection Center on May 13, 2024, and the address is No. 1, Beichen West Road, Chaoyang District, Beijing. Based on the strain, the application also provides the use and related products thereof. The lactobacillus sakei LN-Ls1 can significantly reduce body weight, improve blood lipid level and lipid metabolism without affecting food intake, has a remarkable weight loss and lipid-lowering effect, and has a better technical effect compared with existing products, and has good safety and application prospect.

This invention discloses a method for preparing flavanone extracts through microbial co-fermentation and its application in lipid-lowering activity, belonging to the field of food nutrition and functional components. By co-fermenting orange peel raw materials with yeast and Monascus purpureus, the synergistic metabolic effects of different microorganisms are utilized to increase the content and reconstruct the composition of flavanones from orange peel. The bioactivity of the fermentation products was evaluated using a mouse 3T3-L1 preadipocyte differentiation model. The results showed that the flavanones from orange peel treated with co-fermentation had a significant inhibitory effect on lipid accumulation, and their lipid-lowering activity was significantly better than that of unfermented or single-strain fermentation products. The method of this invention is simple, reproducible, and suitable for large-scale production, and can be applied to the development of lipid-lowering functional health products or dietary supplements.

This invention discloses an edible fungus extract, its preparation method, and its application in the preparation of products that enhance immunity and lower lipids. The edible fungus extract is composed of Ganoderma lucidum water extract and enoki mushroom water extract. The research of this invention shows that the mixture of Ganoderma lucidum water extract and enoki mushroom water extract has the effect of synergistically enhancing immune regulation and lowering lipids, and can be added as a functional food ingredient, providing a basis for the research and development of high-value-added edible fungus products.

This invention relates to a method for treating patients with heterozygous familial hypercholesterolemia (heFH), comprising administering a pharmaceutical composition containing a PCSK9 inhibitor to a patient with heterozygous familial hypercholesterolemia. In some embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, such as the exemplary antibody referred to herein as mAb316P. The method of the present invention can be used to treat patients with heterozygous familial hypercholesterolemia whose cholesterol is poorly controlled with the maximum tolerated dose of statins, with or without other lipid-lowering therapy.

This invention relates to the field of functional food processing technology, and discloses a method for preparing and applying corn peptides that lower blood pressure. First, microwave pretreatment is used to improve the dissolution rate of corn protein. Then, dynamic temperature-controlled synergistic enzymatic hydrolysis combined with time-segmented microwave assistance is used to directionally release hydrophobic ACE-inhibiting peptides. Surface-modified magnetic materials are used to perform biomimetic affinity adsorption and magnetic separation purification of the target peptides, achieving highly selective enrichment of active ingredients. Finally, the peptides are compounded with stabilizers such as tea polyphenol-zinc chelate and Monascus purpureus extract to form a charge-matched micelle protection system. Through dynamic temperature-controlled synergistic enzymatic hydrolysis and biomimetic magnetic separation processes, efficient release and functional enhancement of active peptides are achieved, simultaneously improving ACE inhibitory activity and storage stability. The charge-matching of stabilizers and the synergistic design of components overcome the absorption barrier of active peptides. A multi-pathway regulatory system is constructed, integrating "blood pressure lowering, lipid lowering, and antioxidant" functions. Experiments have demonstrated that this application has a blood pressure lowering effect.

The application discloses a plant lactobacillus gasseri strain capable of transforming ginsenoside and cassia glycoside, and application of the strain in lipid reduction and alleviation of fatty liver, and belongs to the fields of microbial technology, medicine and functional food. The core feature of the strain is that the strain can not only transform ginsenoside Rb1 into ginsenoside Rd with higher activity, but also transform cassia glycoside into cassia glycoside base, thereby improving the efficacy. The animal experiment proves that the strain and the corresponding substrate are combined to play a better role in lipid reduction and liver protection: the serum total cholesterol and triglyceride levels of high-fat diet mice can be effectively reduced, and the liver weight, liver lipid deposition and liver tissue fatty degeneration can be reduced and improved. The strain provides a new core strain and technical scheme for developing microecological preparations for preventing and / or assisting in treating hyperlipidemia, non-alcoholic fatty liver and other metabolic diseases.

This invention relates to the field of functional food technology, specifically to a solid beverage with lipid-lowering, weight-loss, spleen-strengthening, and digestion-aiding effects, and its preparation method. The solid beverage comprises the following ingredients by weight: 2-3 parts modified sodium alginate, 5-8 parts inulin, 2-4 parts orange peel, 3-6 parts red adzuki bean extract, 1.5-3 parts cassia seed extract, 1-2 parts bitter orange flower extract, 2-4 parts radish seed extract, 3-6 parts hawthorn, and 2-4 parts lotus leaf extract. This solid beverage with lipid-lowering, weight-loss, spleen-strengthening, and digestion-aiding effects has the functions of lowering lipids, promoting digestion, weight loss, and spleen strengthening. Combined with dietary fiber such as inulin and resistant dextrin, it helps maintain intestinal function. Modified sodium alginate improves emulsification and dissolving stability. This solid beverage can be used as an auxiliary conditioning drink for overweight and hyperlipidemic individuals.

The present invention relates to the field of peptide drugs, and particularly to a triple-target peptide and a derivative thereof. The triple-target peptide provided by the present invention exerts effects of lowering blood glucose, reducing blood lipids, and weight loss. Based on the above studies, the triple-target peptide provided by the present invention is further long-acting modified, and while retaining excellent effects for the specific indications described above, also has long-acting advantages, which can reduce dosing frequency, improve medication convenience, and enhance patient compliance. Experimental results show that the peptide and the long-acting derivative thereof provided by the present invention can significantly lower blood glucose, reduce blood lipids and / or induce weight loss, and can effectively prevent, treat, or ameliorate diabetes, obesity, obesity-related diseases, or metabolic disorders.

The application belongs to the technical field of medicine, and particularly relates to the use of icariin in the preparation of lipid-lowering drugs with muscle protection. In view of the adverse reactions such as myalgia and myositis caused by the existing statins in the lipid-lowering process, the muscle protection effect of icariin in the lipid-lowering process is evaluated by constructing a high-fat cell model and a high-fat Caenorhabditis elegans model. It is found through research that icariin can significantly reduce the content of triglyceride, total cholesterol and lipid droplet accumulation in high-fat cells, reduce the content of triglyceride and lipid droplet accumulation in high-fat C. elegans, and prolong the lifespan of high-fat C. elegans. Further research shows that icariin can improve the muscle state of high-fat C. elegans while lowering lipid, and the specific performance is the enhancement of the movement ability of C. elegans and the maintenance of the structural integrity of body wall muscle fibers. The application discloses the unique advantage of icariin in the lipid-lowering process, that is, the muscle protection effect, and can solve the adverse reactions such as myalgia and myositis caused by the existing statins, and has an important clinical application prospect.

This invention provides a polysaccharide from *Melia azedarach*, its extraction method, and its applications, belonging to the field of polysaccharide extraction technology. The *Melia azedarach* polysaccharide includes at least one of *Melia azedarach* polysaccharide 1 and *Melia azedarach* polysaccharide 2. *Melia azedarach* polysaccharide 1 comprises the polysaccharide molecule represented by formula (I), and *Melia azedarach* polysaccharide 2 comprises the polysaccharide molecule represented by formula (II). This invention also provides a method for extracting this *Melia azedarach* polysaccharide. This *Melia azedarach* polysaccharide exhibits good effects in fat binding, bile acid binding, cholesterol binding, and lipase inhibition, and has broad application prospects in the preparation of lipid-lowering products.